A.R.A. Marques graduated in Biochemistry (BSc, University of Lisbon; MSc, University of Amsterdam) and currently works at the NOVA Medical School (NMS Research, Portugal). A. R. A. Marques obtained his Ph.D. in Medical Biochemistry at the University of Amsterdam, The Netherlands. During his Ph.D. studies A. R. A. Marques investigated the role of lysosomal homeostasis in neurodegeneration. Afterwards, A. R. A. Marques developed a 3-year PostDoctoral Project at the University of Kiel (Germany), centred on Batten disease (NCL2TREAT Consortium), the most common inherited neurodegenerative disease in children. This project resulted in the registration of an international patent for the treatment of Batten disease, of which he is co-inventor. In 2018, A. R. A. Marques was awarded a contract by the Portuguese Foundation for Science and Technology (FCT), to develop a 6-year project investigating the role of lysosomal dysfunction in atherosclerosis at NMS Research. Presently, his research is focused on the interplay between lipid metabolism and organelle dysfunction in human disease.
